Filing Flows › Health Care › Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals (ZNTL) earnings and revenue breakdown
Latest: Q4 2024 · 10-K filed Mar 26, 2025 · Zentalis Pharmaceuticals (ZNTL) Q4 2024 earnings results →
Q4 2024 177¢ of every $1 of revenue lost · operating margin -185.6%
Zentalis Pharmaceuticals made $26.9M in Q4 2024. Operating margin -185.6%, net loss $47.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 26, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $26.9M in Q4 2024.
Operating costs exceeded revenue by $49.8M, an operating margin of -185.6%. The quarter ended with a net loss of $47.5M.
Operating cash flow was −$39.7M. Non-cash charges added back $317K of depreciation and amortization and $31.4M of share-based compensation. Working capital and other items used $23.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2024 | 10-K | Mar 26, 2025 | $26.9M | — | -185.6% | −$47.5M | −$39.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Zentalis Pharmaceuticals
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1+ platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1+ PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1+ PROC. We exclusively in-license or solely own worldwide development and commercialization rights to azenosertib.
In its own words, from its 10-K, filed Mar 26, 2025.
Zentalis Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -185.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ZNTL Zentalis Pharmaceuticals | Q4 2024 | $26.9M | — | -185.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Zentalis Pharmaceuticals 10-K on SEC EDGAR · CIK 1725160 · Pharmaceutical Preparations
13F: who owns ZNTL and who is buying
More on ZNTL
History
Every quarter: Q4 2024 results